Quantcast

Latest Neuraminidase inhibitors Stories

2010-02-26 09:15:23

A new study shows that a novel antiviral compound is effective against the highly pathogenic H5N1 avian influenza virus, including oseltamivir (Tamiflu)-resistant strains, according to scientists from Japan, Vietnam, Indonesia, and the University of Wisconsin-Madison. The research, published February 26 in the open-access journal PLoS Pathogens, suggests that the prodrug CS-8958 is a promising alternative antiviral for prevention and treatment of H5N1 influenza. Antiviral drugs are a primary...

2010-02-22 08:30:00

EMERYVILLE, Calif., Feb. 22 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, reported today on the publication of results from a preclinical study that demonstrated the synergistic effects of triple combination antiviral drug (TCAD) therapy against multiple strains of seasonal, pandemic, and avian influenza A (H1N1, H3N2 and H5N1) virus, including three strains of amantadine resistant pandemic H1N1 and two strains of oseltamivir resistant seasonal H1N1. The results...

2010-02-18 06:00:00

BIRMINGHAM, Ala., Feb. 18 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Stuart Grant, Senior Vice President and Chief Financial Officer of BioCryst, plans to speak as a participant on the Biodefense Panel at RBC Capital Market's Healthcare Conference in New York on Tuesday, March 2, 2010 at 3:35 to 4:30 p.m. Eastern Time. Links to a live audio Web cast and replay of the panel discussion may be accessed on the BioCryst Web site at...

2010-02-16 14:41:44

An increased dosage of Tamiflu (oseltamivir) for patients with critical illness is unlikely to be required in the treatment of pandemic (H1N1) influenza, contrary to current international guidelines, found a new study in CMAJ (Canadian Medical Association Journal). World Health Organization (WHO) guidelines recommend that all critically ill patients should be treated with Tamiflu and if the patient was unresponsive to standard doses or critically ill, a higher dose should be considered. The...

2010-02-02 06:08:00

LOURES, Portugal, February 2 /PRNewswire/ -- Hovione is announcing the filing of a new drug application in Japan by its licensee Daiichi Sankyo Company Ltd. for the influenza drug CS-8958, which is delivered using Hovione's TwinCaps(R) inhaler. Being pre-filled, disposable and low-cost, TwinCaps(R) was specifically developed for the influenza indication and may thus be used for inhaled drug delivery to the lung in other acute indications, such as bacterial or viral infections. Since...

2010-02-01 18:10:32

A targeted program of preventive antiviral medication, combined with the use of hand sanitizers and surface decontamination, was associated with containing the spread of the H1N1 virus in a summer camp setting, according to a report posted online today that will appear in the April print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals. Since spring 2009, millions of Americans have been infected with the novel influenza A(H1N1) virus and thousands...

2010-02-01 09:50:00

TAMPA, Fla., Feb. 1 /PRNewswire/ -- Romark Laboratories announced that it has initiated enrollment of patients in a clinical trial of Alinia® (nitazoxanide) for treating acute uncomplicated influenza including illness caused by the currently circulating H1N1 strain. (Logo: http://www.newscom.com/cgi-bin/prnh/20100201/FL47022 ) The clinical trial is being conducted in approximately 25 sites across the United States and is expected to enroll 440 adult patients with...

2010-01-26 08:24:00

BIRMINGHAM, Ala., Jan. 26 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its partner, Shionogi & Co., Ltd. will launch RAPIACTA, intravenous (i.v.) peramivir anti-viral, to treat patients with influenza in Japan, on January 27, 2010. An English version of Shionogi's press release announcing this launch is available on the web at: http://www.shionogi.co.jp/ir_en/news/detail/e_100126.pdf On January 13, 2010, Shionogi received the world's...

d152e6b7e00021ac75d9e282feda48a11
2010-01-14 11:43:26

Scientists have developed an alternative method for producing the active ingredient in Tamiflu®, the mainstay for fighting H1N1 and other forms of influenza. The new process could expand availability of the drug by reducing its cost, which now retails for as about $8 per dose. Their study is in ACS' Organic Letters, a bi-weekly journal. Anqi Chen, Christina Chai and colleagues note that the global pandemic of H1N1 has resulted in millions of infected cases worldwide and...

2010-01-13 06:00:00

BIRMINGHAM, Ala., Jan. 13 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its partner, Shionogi & Co., Ltd. has received marketing and manufacturing approval for intravenous (i.v.) peramivir to treat patients with influenza in Japan. Shionogi intends to commercially launch peramivir under the commercial name RAPIACTA in Japan, pending the product's National Health Insurance (NHI) price listing. As a result of this approval, BioCryst will...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related